The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Venetoclax and BEAM followed by ASCT for R/R NHL
Joseph Maakaron, MD, University of Minnesota, Minneapolis, MN, discusses the results of a Phase I dose-escalation study investigating venetoclax plus BEAM followed by autologous stem cell transplant (ASCT) for chemoresistant or high-risk relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). In this trial, venetoclax and BEAM demonstrated promising results as a safe and well-tolerated approach in a typical, elderly population. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
